Huntington's Disease Research

Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.

Huntington's Disease Research Products Targets

Products for Huntington's Disease Research - Page 42

Cat.No. Product Name Information/Activity
BCC7045 (RS)-3,4-DCPG 176796-64-8
BCC7012 (S)-3,4-DCPG 201730-11-2
BCC7652 NPEC-caged-(S)-3,4-DCPG 1257323-85-5
BCC6578 O-Phospho-L-serine O-Phospho-L-serine is the immediate precursor to L-serine in the serine synthesis pathway, and an agonist at the group III mGluR receptors (mGluR4, mGluR6, mGluR7, and mGluR8); O-Phospho-L-serine also acts as a weak antagonist for mGluR1 and a potent antagonist for mGluR2.
BCC6975 (RS)-PPG (RS)-PPG is a potent and selective agonist for group III mGluRs. The EC50s of 5.2 μM, 4.7 μM, 185 μM, and 0.2 μM for hmGluR4a, hmGluR6, hmGluR7b, and hmGluR8a, respectively. Anticonvulsive and neuroprotective activity.
BCC7615 VU 0155041 1093757-42-6
BCC7642 VU 0155041 sodium salt 1259372-69-4
BCC7616 Z-Cyclopentyl-AP4 103439-17-4
BCC6872 CPPG CPPG ((RS)-CPPG) is a potent group II/III mGlu receptor antagonist. CPPG exhibits some selectivity (approximately 20 fold) for group III (IC50=2.2 nM) over group II (IC50=46.2 nM) mGlu receptors in the rat cerebral cortex. CPPG has weak effects at group I mGlu receptors.
BCC7528 MMPIP hydrochloride 479077-02-6